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Abstract
Background: Anemia and vitamin D deficiency are common factors in chronic heart failure (CHF). 
The aim of this study was to assess vitamin D levels as well as its binding protein and anemia in rela-
tion to a cause of CHF: coronary heart disease, valvular disease and cardiomyopathy. 
Methods: One hundred and sixteen consecutive patients (36 females and 80 males) with CHF were 
admitted for percutaneous coronary interventions (PCI). Hemoglobin concentration, serum creatinine, 
B-type natriuretic peptide (BNP), 25-hydroxyvitamin D [25(OH)D] and its binding protein-VDBP 
were measured.
Results: The prevalence of anemia was 22%. BNP was the highest in the group with coronary artery 
disease. Ejection fraction was the lowest in cardiomyopathy group. 25(OH)D was lowest in valvular 
disease group, significantly lower than in the coronary artery group. A similar pattern of change showed 
vitamin D binding protein. The prevalence of vitamin D deficiency (level below 20 ng/mL) in the whole 
group was 95%, in 49% of the patients 25(OH)D was below 10 ng/mL. In univariate analysis 25(OH)D  
correlated with hemoglobin, red blood cell count, hematocrit, mean corpuscular volume and BNP in 
patients with CHF in the whole group. In multiple regression analysis, predictors of 25(OH)D were 
estimated, glomerular filtration rate, BNP and valvular disease.
Conclusions: 25(OH)D deficiency is common in CHF patients. Valvular disease is associated the most 
severe vitamin D deficiency and worsened kidney function. A higher prevalence of anemia in CHF due 
to coronary heart disease may be associated with wider use of angiotensin converting enzyme inhibitors 
and acetylsalicylic acid. Heart and kidney function are predictors of 25(OH)D level in the patients of 
this study. (Cardiol J XXXX; XX, X: xx–xx)
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Introduction
Heart failure (HF) is a common clinical syn-
drome caused by a variety of cardiac diseases [1]. 
HF prevalence has been increasing recently due 
to an aging population and prolongation of life by 
modern therapeutic innovations. Despite improve-
ments in therapy, the mortality rate in patients 
with HF has remained unacceptably high [1]. In the 
1970s, hypertension and coronary disease, particu-
larly myocardial infarction (MI), were the primary 
causes of HF in the United States and Europe [1–3]. 
However, coronary artery disease (CAD) and diabe-
tes mellitus have become increasingly responsible 
for HF while hypertension and valve disease have 
become less common because of improvements in 
diagnosis and therapy [4–7]. Risk factors for HF 
include coronary heart disease, cigarette smoking, 
hypertension, obesity, diabetes, and valvular heart 
disease [5, 8]. Vitamin D deficiency and anemia are 
frequent findings in HF [1–4]. It was previously 
shown that the prevalence of anemia in a cohort 
undergoing percutaneous coronary intervention 
(PCI) was 21% and related to the New York Heart 
Association (NYHA) class [9].
Taking all these data into consideration, in-
cluding fact that studies on anemia and 25-hy-
droxyvitamin D [25(OH)D] in HF are scarce and 
equivocal, this cross-sectional study was designed 
to investigate: a) the prevalence of anemia and 
vitamin D deficiency in patients with HF due to 
CAD, cardiomyopathy or valvular disease undergo-
ing PCIs; b) relation between 25(OH)D, its binding 
protein and anemia in these three subpopulations. 
Methods
The study was performed on 116 consecutive 
patients: 36 females and 80 males with chronic 
HF with reduced ejection fraction admitted to the 
Department of Invasive Cardiology for PCIs. The 
criteria for patients with HF to be included in the 
study were according to the European Society 
of Cardiology (ESC) guidelines from 2016 [10]: 
1) age ≥ 18 years; 2) documented history of HF 
of ≥ 6 months; 3) left ventricular ejection fraction 
(LVEF) ≤ 40% as assessed by echocardiography 
(performed at the beginning of the study, using the 
Simpson planimetric method); 4) clinical stability 
and unchanged medications for ≥ 1 month prior to 
the study. Patients were divided into three sub-
groups: group I — patients with chronic HF due to 
CAD (n = 40); group II — patients with HF due to 
cardiomyopathy (n = 31); and group III — patients 
with HF due to valvular disease without signs or 
symptoms of CAD (n = 45).
Exclusion criteria included: 1) acute coronary 
syndrome or coronary revascularization within 
3 months before the study; 2) unplanned hospitali-
zation due to HF deterioration or any other cardio-
vascular reason within 1 month before the study; 
3) any acute or chronic illness that might influence 
iron metabolism (including malignancy, infection, 
chronic kidney disease [CKD] requiring renal re-
placement therapy, and hematological diseases); 
4) any anemia and/or iron deficiency treatment 
either at the beginning or during 12 months prior 
to the study. The study protocol was approved by 
the local ethics committee and all subjects gave in-
formed written consent. The study was conducted 
in accordance with the Declaration of Helsinki. In 
all patients, venous blood samples were taken in 
the morning following an overnight fast and after 
lying supine at rest for at least 15 min. Hematologi-
cal parameters were assessed from fresh venous 
blood sampled with ethylenediaminetetraacetic 
acid (EDTA). Biochemical parameters were as-
sessed in clotted samples. After centrifuging, 
serum was collected and frozen at –80oC until 
laboratory analysis. 
The following blood biomarkers were meas-
ured directly: hemoglobin concentration, serum 
creatinine, B-type natriuretic peptide (BNP) were 
assayed by standard laboratory methods in the 
central laboratory at the University Hospital. 
Estimated glomerular filtration rate (eGFR) was 
assessed using Chronic Kidney Disease Epide-
miology Collaboration equation (CKD-EPI) [11]. 
Creatinine clearance was estimated using the 
Cockcroft-Gault formula (creatinine clearance = 
(140 – age) × body weight/serum creatinine × 72 
if female × 0.85) [12]. 25(OH)D was assayed using 
commercially available kits from Gentaur, Kampen-
hout, Belgium and its binding protein (VDBP) using 
assays from R&D, Minneapolis, MN, USA. Kidney 
function was assessed either by serum creatinine 
or creatinine clearance according to Cockcroft-
Gault formula. 
Anemia was defined according to the World 
Health Organization (WHO) criteria, i.e., hemoglo-
bin below 12 g/dL in females and 13 g/dL in males 
[13]. According to the WHO, vitamin D insufficiency 
is defined as serum 25(OH)D below 20 ng/mL (50 
nmoL/L) [14]. However, Holick [15] defined vita-
min D deficiency as serum 25(OH)D level below 
20 ng/mL and vitamin D insufficiency as less than 
30 ng/mL (75 nmoL/L). The rationale to change 
the definition was based on the finding that serum 
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parathyroid hormone, which correlated negatively 
with serum 25(OH)D, declined as serum 25(OH)D 
raised and achieved a plateau at a serum 25(OH)D 
of approximately 30 ng/mL (75 nmoL/L) [16, 17].
Statistical analysis
The statistical significance of differences be-
tween the groups was tested using either analysis 
of variance with F statistics, the Student t test, or c2 
test, where appropriate. The associations between 
variables were assessed using the univariate Pear-
son correlation coefficients or the Spearman rank 
correlation coefficients. A value of p < 0.05 was 
considered statistically significant. The multiple 
regression analysis was used to determine inde-
pendent factors affecting the dependent variables. 
Factors showing linear correlation with 25(OH)D 
(p < 0.1) were included in the analysis. All statisti-
cal analyses were performed using Statistica 13.1.
Results
According to the definition, the prevalence 
of anemia in the studied cohort was 22% (18% in 
females and 25% in males). In NYHA class I preva-
lence of anemia was 11%, in class II — 22%, in class 
III — 23%, and 31% in class IV (p < 0.01 for trend). 
Baseline clinical and biochemical characteristics 
of the population studied is presented in Table 1. 
The group with cardiomyopathy was significantly 
younger than the two other groups. The degree of 
HF is reflected by NYHA class (median value was 
2 in all groups) and did not differ between groups 
studied, however BNP was the highest in the 
group with CAD and LVEF was the lowest in the 
cardiomyopathy group. Kidney function assessed 
either by serum creatinine or creatinine clearance 
according to the Cockcroft-Gault formula, which 
included body weight, which were similar, whereas 
eGFR was significantly higher in the cardiomyopa-
thy group when compared to the valvular disease 
group. 25(OH)D was lowest in valvular disease 
and cardiomyopathy group, significantly lower 
than in the coronary artery group. VDBP was 
significantly lower in group III relative to group I. 
When the definition of Holick was adopted [15], 
the prevalence of vitamin D deficiency in the whole 
group was 95%, only 6 patients had vitamin levels 
higher than 20 ng/mL, all of them in group I. Serum 
25(OH)D below 10 ng/mL was found in 49% of the 
patients studied, 40% in group I, 45% in group II 
and 60% in group III, respectively. When patients 
were classified as anemic/non-anemic it was found 
that in group I, serum iron was lower in anemic 
relative to non-anemic patients (39 ± 17 vs. 80 ± 
33 µg/dL, p < 0.01), as well as eGFR by CKD-EPI 
(69 ± 33 vs. 86 ± 31 mL/min/1.73 m², p < 0.05). In 
group II in anemic patients eGFR by CKD-EPI was 
lower relative to non-anemic patients (69 ± 33 vs. 
93 ± 37 mL/min/1.73 m², p < 0.05). In group III, 
NYHA class was higher in anemic patients when 
compared to their non-anemic counterparts (3 ± 1 
vs. 2 ± 0.5, p < 0.05). In univariate analysis vi-
tamin D correlated with hemoglobin (r = 0.61, 
p < 0.01; Fig. 1), red blood cell count (r = 0.42, 
p < 0.05), hematocrit (r = 0.44, p < 0.01), mean 
corpuscular volume (MCV; r = 0.25, p < 0.05) and 
BNP (r = 0.30, p < 0.01; Fig. 2) in patients with 
HF (in the whole group). Vitamin D binding protein 
was related to age (r = 0.21, p < 0.05; Fig. 3). 
In the multivariable-adjusted logistic regres-
sion analyses on the etiology of HF, predictors of 
25(OH)D were eGFR (r = 0.38, p = 0.004), BNP 
(r = 0.41, p = 0.003) and valvular etiology (r = 0.29, 
p = 0.005), adjusted R2 was 45%, F (4,53), 
p < 0.001, SE = 6.82. 
Discussion
In the present study, 25(OH)D concentration 
was assessed together with its binding protein in 
patients with HF referred for coronary angiography. 
The main finding in the current study was a high 
prevalence of vitamin D deficiency (almost 100% 
in the whole group) and an especially profound 
vitamin D deficiency (< 10 ng/mL) in HF patients. 
25(OH)D was lowest in patients with HF due to 
valvular disease, significantly lower than in patients 
with CAD. In the present study, all patients had 
25(OH)D lower than 30 ng/mL. Almost 50% of 
the population studied had 25(OH)D lower than 
10 ng/mL. It was also found that VDBP was low-
est in the valvular disease group relative to the 
coronary artery group. Measurements were done 
in the winter time. 25(OH)D levels in 24 heathy 
age and sex matched volunteers were also assessed 
and it was found that 8 of them had 25(OH)D levels 
below 20 ng/mL, but higher than 10 ng/mL. Mean 
level was 22 ± 7 ng/mL, and the VDBP level was 
337 ± 55 µg/mL. It was highly significant,  above 
(p < 0.001) than in the studied population. As 
reported in the literature, the bone-centric guide-
lines recommend a target 25(OH)D concentration 
of 20 ng/mL (50 nmol/L), and age-dependent daily 
vitamin D doses of 400–800 IU. The guidelines 
focused on pleiotropic effects of vitamin D recom-
mend a target 25(OH)D concentration of 30 ng/mL 
(75 nmol/L), and age, body weight, disease status, 
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and ethnicity-dependent vitamin D doses ranging 
between 400 and 2000 IU/day [18, 19]. 
Kolaszko et al. [20] assessed 25(OH)D levels 
in patients hospitalized in the cardiology ward 
with regard to a presence or absence of HF. It was 
found that these groups did not differ with regard 
to 25(OH)D levels. In addition, 25(OH)D levels 
were similar in patients with or without CAD, 
Table 1. Clinical and biochemical characteristics of groups studied.
Group I  
Coronary  
heart disease
Group II  
Cardio- 
myopathy
Group III  
Valvular 
 disease
P
Age [years] 68 ± 11 61 ± 10 67 ± 10 I vs. II: p < 0.01 
II vs. III: p < 0.01
Anemic patients 29% 20% 21% I vs. II: p < 0.05
Hemoglobin [g/dL] 13 ± 12 14 ± 2 13 ± 2 NS
Hematocrit [%] 40 ± 5 42 ± 5 40 ± 5 NS
Erythrocyte count [×1012/µL] 4.5 ± 0.5 4.7 ± 0.5 4.5 ± 0.6 NS
MCV [fL] 89 ± 5 90 ± 5 89 ± 4 NS
Iron [µg/dL] 65 ± 33 88 ± 33 89 ± 44 I vs. II: p < 0.01 
I vs. III: p < 0.001
Ferritin [ng/mL] 167 (79;246) 175 (113; 276) 115 (75;193) II vs. III: p < 0.05
Transferrin saturation [%] 23 ± 12 29 ± 13 28 ± 14 I vs. II: p < 0.05 
I vs. III: p < 0.05
Functional iron deficiency 7% 8% 11% NS
Absolute iron deficiency 5% 6% 9% NS
Vitamin D [ng/mL] 13 ± 6 10 ± 5 10 ± 3 I vs. II: p < 0.05 
I vs. III: p < 0.05
Vitamin D binding protein [µg/mL] 281 ± 106 262 ± 51 245 ± 81 I vs. III: p < 0.05
Vitamin D deficiency 85% 100% 100% I vs. II: p < 0.05 
I vs. III: p < 0.05
Creatinine [mg/dL] 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.3 NS
Creatinine clearance [mL/min] 70 ± 22 72 ± 21 67 ± 17 NS
eGFR by CKD-EPI [mL/min/1.72 m2] 81 ± 31 88 ± 34 71 ± 21 II vs. III: p < 0.05
CKD prevalence 27% 30% 25% NS
Ejection fraction [%] 29 ± 8 24 ± 7 40 ± 16 I vs. II: p < 0.05 
I vs. III: p < 0.01 
II vs. III: p < 0.01
BNP [pg/mL] 328 (210; 723) 263 (125; 599) 227 (81; 466) I vs. III: p < 0.05
Hypertension 61% 57% 61% NS
Diabetes 32% 19% 28% NS
Atrial fibrillation 23% 33% 38% NS
ACEI 94% 97% 76% I vs. III: p < 0.001 
II vs. III: p < 0.001
ASA 94% 64% 55% I vs. II: p < 0.001 
I vs. III: p < 0.001
Thienopyridines 60% 24% 22% I vs. II: p < 0.001 
I vs. III: p < 0.001
Anticoagulants 11% 33% 31% I vs. II: p < 0.01 
I vs. III: p < 0.001
Diuretics 79% 87% 67% I vs. III: p < 0.05 
II vs. III: p < 0.001
Data given are percentages, means ± standard deviation or median and interquartile ranges. ACEI — angiotensin converting enzyme inhibitors; 
ASA — acetylsalicylic acid; BNP — B-type natriuretic peptide; CKD — chronic kidney diseaese; CKD-EPI — Chronic Kidney Disease Epidemiology 
Collaboration equation; eGFR — estimated glomerular filtration rate; MCV — mean corpuscular volume 
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however, the prevalence of vitamin D deficiency or 
insufficiency was not reported. The mean level of 
25(OH)D in the present study was 12 ± 5 ng/mL 
in HF and samples were taken in the winter time, 
similar to the paper by Kolaszko et al. [20]. Being 
fully aware of seasonal variations [21] data was not 
collected on dietary supplements of vitamins and 
other nutrients as well as medications affecting 
bone health (i.e. steroids). The population herein 
was slightly older than those studied by Kolaszko 
et al. [20]. Moreover, 25(OH)D was assessed and 
its binding protein in HF patients of three different 
etiologies, while in previous studies etiology was 
not taken into account. Renal function as reflected 
by eGFR was comparable to the Kolaszko et al. 
[20] study. Polat et al. [22] reported that lowered 
25(OH)D concentration in HF due to cardiomyopa-
thy was related to severity of the disease. In the 
present study, there was no correlation between 
LVEF and 25(OH)D in any group studied. 
In the Pandey et al. [23] study  more than 90% 
of HF patients with preserved ejection fraction had 
25(OH)D insufficiency, and 30% were deficient. It 
was also associated with exercise intolerance as 
reflected by lower peak VO2 and 6-minute walk 
distance in HF with preserved ejection fraction. 
Saponaro et al. [24] evaluated the levels of vitamin D 
in patients with HF and were compared to a con-
trol group to assess the effects of vitamin D on HF 
outcome. They reported that patients with HF 
had statistically lower 25(OH)D levels (p < 0.001) 
and a statistically higher prevalence of vitamin D 
insufficiency (61.1% vs. 39.5%, p < 0.001) and 
deficiency (24.7% vs. 6.6%, p < 0.001), relative 
to the healthy controls. In addition, a significant 
inverse relationship was observed between base-
line 25(OH)D and risk of HF-related death, having 
a hazard ratio of 0.59 (95% confidence interval 
0.37–0.92, p = 0.02), and was confirmed in a mul-
tivariate adjusted analysis. In corroboration with 
this study, Walker et al. [25] in a prospective cohort 
study of 1802 patients with chronic HF and LVEF 
≤ 45% found that sepsis was the major cause of 
death in their study. As sepsis death was indepen-
dently associated with lower log serum vitamin D 
than non-sepsis death, and vitamin D supplemen-
tation was suggested to possibly  be one of the 
targeted preventative strategies.
Pludowski et al. [26] evaluated the 25(OH)D 
concentration in a representative group of 5775 
adult volunteers in 22 Polish cities. Conducted 
Figure 3. Correlation between vitamin D binding protein 
and age in heart failure patients.
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Figure 1. Correlation between hemoglobin and 25(OH)D 
in heart failure patients.
Figure 2. Correlation between B-type natriuretic peptide 
(BNP) and 25(OH)D in heart failure patients.
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in late winter, mean and median concentration of 
25(OH)D were 18 ± 10 ng/mL and 16 ng/mL, re-
spectively. In the whole group (spring and winter 
measurements) serum 25(OH)D levels lower than 
20 ng/mL were found in 66%. Also reported, 16% 
of the participants had surprisingly low levels of 
25(OH)D i.e. below 10 ng/mL. In the current study, 
49% of the participants had 25(OH)D lower than 
10 ng/mL. In the study performed in northern Poland 
on 448 adults from February to mid-April, the mean 
25(OH)D level was 14 ± 7 ng/mL years and 84% 
had a concentration of less than 20 ng/mL (< 50 
nmol/L) [27]. Similar data came from a study on 
274 elderly (mean age 69 years) postmenopausal 
women living in Warsaw [28]. The mean 25(OH)D 
level was 14 ng/mL (winter time) and 83% had 
25(OH)D deficiency. A debate continues on the 
lower limit of normal for 25(OH)D levels, which 
depends upon geographic location and sunlight 
exposure of the reference population. Moreover, 
there is no consensus on optimal 25(OH)D con-
centration for skeletal or extraskeletal health. 
The Institute of Medicine concluded that a serum 
25(OH)D concentration of 20 ng/mL (50 nmol/L) 
is sufficient for most individuals [29], but other 
experts (Endocrine Society, National Osteoporo-
sis Foundation [NOF], International Osteoporosis 
Foundation [IOF], American Geriatrics Society 
[AGS]) suggest that a minimum level of 30 ng/mL 
(75 nmol/L) is necessary in older adults to mini-
mize the risk of falls and fractures [30–32]. Zhang 
et al. [33]. reported a plateau above 20 ng/mL for 
incidence, but much higher for mortality. In the 
Moli-sani study vitamin D deficiency was associ-
ated, independently of known HF risk factors, with 
an increased risk of hospitalization for HF in an 
Italian adult population [34].
In the present study, a vast majority of patients 
had vitamin D deficiency,  could not be solely as-
cribed  to impaired kidney function. Other causes 
of 25(OH)D deficiency include: decreased intake 
or absorption, reduced sun exposure, increased 
hepatic catabolism, decreased endogenous syn-
thesis (via decreased 25-hydroxylation in the liver 
or 1-hydroxylation in the kidney), or end-organ 
resistance to 25(OH)D. Winter levels of 25(OH)D 
mainly depend on food intake and previous liver 
storage. Dietary assessment was not performed in 
the present population studied. As cutaneous vita-
min D production and vitamin D stores decline with 
age [35], this explanation may also be considered, 
at least partially. In addition to reduced endogenous 
production, vitamin D intake is often low in older 
subjects. It has been also reported that in hospital-
ized patients, 25(OH)D deficiency defined as level 
< 15 ng/mL) was found in 57%, of whom 22% were 
considered severely deficient (serum concentration 
of 25(OH)D < 8 ng/mL) [36]. As shown, predictors 
of vitamin D deficiency were inadequate vitamin D 
intake, winter season, and housebound status. As 
vitamin D deficiency may be dependent, in part, 
upon the age of  patients on hospital wards [37, 38], 
it should be stressed that in a subgroup of patients 
< 65 years without known risk factors, vitamin D 
deficiency was still detected in 42% [35] of them. 
As it has been reported previously [39], vitamin D 
deficiency predisposes up-regulation of renin–an-
giotensin–aldosterone (RAA) system, causes left 
ventricle hypertrophy and vascular smooth muscle 
cell hypertrophy as well. 
Anemia was found in 22% of patients  stud-
ied. Its prevalence rose significantly with NYHA 
class (from 11% in class I to 31% in class IV). A 
subclinical inflammatory state was reported, as 
reflected by elevated levels of cytokines, hemodilu-
tion, dietary deficiencies including iron and other 
microelements, the use of medications affecting 
RAA system, CKD, poor nutrition and decreased 
bone marrow perfusion may all contribute to the 
development of anemia in HF [40–42]. Inflam-
matory cytokines or high sensitivity C-reactive 
protein were not studied in the present patients, 
however, CKD was present in 25–30% of patients 
as well as iron deficiency (both absolute and func-
tional) was diagnosed in 12–20% depending on 
the HF etiology, in addition a vast majority of the 
patients were treated with drugs affecting the RAA 
system, and as well as acetylsalicylic acid (ASA) 
and anticoagulants. Therefore, the high preva-
lence of anemia in the studied group appears to be 
multifactorial with an important role of CKD as a 
subclinical inflammatory state and iron deficiency. 
In addition, therapy of chronic HF with the RAA 
system blockade and use of other drugs potentially 
contributed as anticoagulant to the presence of 
anemia in this population. Higher prevalence of 
anemia of valvular origin of chronic HF might be 
associated with a higher prevalence of impaired 
kidney function as reflected by lower eGFR and 
creatinine clearance, higher prevalence of iron 
deficiency (both absolute and functional). 
As reviewed previously, angiotensin convert-
ing enzyme inhibitors (ACEI)/angiotensin II recep-
tor blockers (ARB) can decrease hemoglobin levels 
by 0.2–0.3 g/dL [43]. ACEI declined vascular resist-
ance in efferent arterioles in glomeruli, increased 
oxygenation in the peritubular region and thereby 
lowered the signal for synthesis of erythropoietin. 
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The tetrapetide N-acetyl-Ser–Asp–Lys–Pro (Ac-
SDKP) named goralatide or seraspenide, a normal 
inhibitor of entry for pluripotent cells into the 
S-phase, is metabolized by ACE. During therapy 
with ACEI, Ac-SDKP can accumulate and cause 
a decline in erythropoiesis [44]. 
Findings in the present study show a cor-
relation between 25(OH)D and anemia in pa-
tients with HF. It may be due to the fact, that 
patients with worse kidney function and anemia had 
a lower 25(OH)D. In other studies associations 
were found in patients scheduled for cardiac sur-
gery and coronary angiography [45–47]. However, 
in the randomized controlled trials two studies 
reported no effect of vitamin D in anemia [48, 
49], while two others performed in CKD showed 
a beneficial effect of vitamin D on the dose of eryth-
ropoietin stimulating agents [50, 51]. In Effect of 
Vitamin D on Mortality in Heart Failure (EVITA) 
trial vitamin D supplementation had no effect on 
anemia prevalence in advanced HF patients [52]. In 
the EVITA trial prevalence of anemia was 17% in 
the treatment group and 11% in the placebo group, 
whereas at termination of the study, the prevalence 
was much higher, reaching 32% in both groups. No 
data on iron status were provided. In the current 
study, prevalence of iron deficiency (absolute and 
functional) was close to 20%. However, no correla-
tions were found between iron parameters, 25(OH)
D and its binding protein. It was assumed that there 
may simply be no causal relationship between ane-
mia, iron status and 25(OH)D in HF. It is well estab-
lished that vitamin D deficiency is highly prevalent 
in patients with CKD undergoing renal replacement 
therapy [53]. This supports the findings that kidney 
function was a predictor of 25(OH)D in HF. As shown 
previously, prevalence of CKD was high in patients 
undergoing PCI despite normal serum creatinine, 
particularly in higher NYHA class [53, 54]. It cor-
roborates with the present study that BNP was also 
a predictor of 25(OH)D in HF patients.
Limitations of the study
This study has several strengths and, on the 
other hand, several limitations. As all patients 
underwent coronary angiography, we were able 
to divide the cohort with regard to the etiology of 
HF. Moreover, vitamin D binding protein as well 
as detailed iron status data was also assessed. 
A limitation could be a lack of assessment of 
parathyroid hormone, calcium, phosphate and 
cross-sectional design. Other limitations include 
retrospective data analysis, and no advanced statis-
tical approach to analyze independent associations. 
Conclusions
Vitamin D deficiency is very common in HF 
patients, predominantly in valvular disease. Higher 
prevalence of anemia in HF due to CAD may be 
associated with wider ACEI and ASA use relative to 
other etiologies. Correlation between anemia and 
25(OH)D are of interest but require further study 
to elucidate possible pathogenetic mechanism(s) 
and also do not provide a rationale for vitamin sup-
plementation. However, heart and kidney function 
are predictors of 25(OH)D level.
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